1250 Broadway, 27th Floor New York, NY 10001

THIS IS NEEDLING ME

fda_logo_nyreblog_com_.gifAmerican Regent Initiates Nationwide Voluntary Recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%, 50mL Single Dose Vials Due to Particulate Matter

American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products:

Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial NDC # 0517-0639-25

and

Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL, Single Dose Vial NDC # 0517-1550-25

PLEASE NOTE: This recall, initiated on December 23, 2010 to the User or Consumer Level is for ALL unexpired lots of Sodium Bicarbonate Injection, USP, 7.5% and 8.4%, 50 mL Single Dose Vials. See attached APPENDIX for ALL the lots subject to this voluntary recall.

This voluntary recall was initiated because some vials of these lots contain particulates. Potential adverse events after intravenous administration include damage to blood vessels in the lung, localized swelling, and granuloma formation. American Regent is undertaking this recall in consideration of the potential for safety issues if these lots of product are administered to patients.

Sodium Bicarbonate Injection, USP, is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate is also indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.

The product was distributed to wholesalers and distributors nationwide.

Hospitals, infusion centers, clinics and other healthcare facilities should not use American Regent Inc., Sodium Bicarbonate Injection, USP, 7.5% and 8.4%, 50 mL Single Dose Vials with the lot #s on the attached list for patient care and should immediately quarantine any product for return.

"The safety of patients receiving our products is our primary concern. All of us at Luitpold Pharmaceuticals and American Regent are committed to taking the necessary steps to protect patients from any potential safety risks with our Sodium Bicarbonate Injection," said Mary Jane Helenek, President and CEO of American Regent.

While American Regent continues to investigate this issue, the company is taking precautionary action and initiated this voluntary recall. American Regent has informed the FDA of its actions and is maintaining ongoing discussions with the agency.

As is standard practice, and as stated in the Sodium Bicarbonate Injection, USP Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

American Regent is notifying its distributors and consumers by email, facsimile and/or overnight courier and is arranging for return of all recalled product. Consumers/distributors/retailers that have product which is being recalled should stop use.

American Regent will credit accounts for all returned product with these lot #'s. Those with questions about the return process, please call our Customer Service Department at 1-800-645-1706: Monday thru Friday from 8:30AM to 7:00PM ET.

Hospitals, infusion centers, clinics and healthcare providers, or patients with other questions may contact the Professional Services Department at 800-645-1706.

Any adverse reactions experienced with the use of this product, and/or quality problems should be reported to American Regent, Inc. via email at PV@luitpold.com , by fax to 610-650-7781 or 610-650-0170 or by phone at 1-800-734-9236.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.

Sodium Bicarbonate Injection, USP is manufactured by Luitpold Pharmaceuticals, Inc. and is distributed by American Regent, Inc. (Shirley, NY).

Source: Luitpold Pharmaceuticals, Inc.

This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

APPENDIX

American Regent Recall Lots of Sodium Bicarbonate Injection, USP

Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial NDC # 0517-0639-25

Lot Expire Date
8833 Dec-2010
9130 Feb-2011
9342 May-2011
9543 Aug-2011
9702 Oct-2011
0068 Feb-2012
0276 Apr-2012
0581 Aug-2012
0745 Nov-2012

Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL Single Dose Vial NDC # 0517-1550-25

Lot Expire Date
8845 Dec-2010
9062 Jan-2011
9058 Feb-2011
9111 Feb-2011
9128 Feb-2011
9158 Mar-2011
9180 Mar-2011
9212 Mar-2011
9262 Apr-2011
9271 Apr-2011
9292 Apr-2011
9346 May-2011
9346A May-2011
9360 May-2011
9374 May-2011
9396 Jun-2011
9412 Jun-2011
9438 Jun-2011
9720 Oct-2011
9801 Nov-2011
9821 Nov-2011
0054 Jan-2012
0115 Feb-2012
0162 Mar-2012
0172 Mar-2012
0237 Apr-2012
0427 Jun-2012
0528 Aug-2012
0597 Sep-2012
0649 Sep-2012

###

Categories: